Biotech Vertex Pharmaceuticals stock tumbled on news of disappointing drug data. CEO Reshma Kewalramani paid nearly $4 ...

It's the second time this year the stock has slumped significantly in one day, and it might represent another attractive ...

And one of the best ways to cash in on that is to invest in stocks that can exceed the market's performance. Two that look ...

Vertex Pharmaceuticals shows promising signs despite a recent price drop. Strong fundamentals underscore its market position, ...

A joint venture led by locally based REIT Diversified Healthcare Trust (NASDAQ: DHC) has received $1 billion for the refinancing of the Vertex Pharmaceuticals headquarters facility in Boston. A ...

Vertex Pharmaceuticals Incorporated has been a hot topic lately, but it's crucial to dig into the details before investing.

The RMR Group secured a $1 billion refinancing for Vertex Pharmaceuticals' Boston Seaport headquarters, a five-year, interest ...

The Q2 pharma earnings season featured changes in the obesity race as well as insights into drugmakers’ views on tariffs and drug pricing.

Thousands of Massachusetts biotech employees face job losses amid industry turmoil. Laid-off workers share their struggles ...

Brinsupri, which Insmed acquired from AstraZeneca nearly a decade ago, is the first treatment for bronchiectasis that’s not ...

Vertex Pharmaceuticals' unchanged guidance and disappointing trial outcomes for its investigative pain relief treatment led ...

Vertex Pharmaceuticals' Seaport headquarters buildings have been refinanced for $1 billion, putting a ten-figure value on an ...